HomeComparePPCBD vs MRK

PPCBD vs MRK: Dividend Comparison 2026

PPCBD yields 35.21% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PPCBD wins by $121.2K in total portfolio value
10 years
PPCBD
PPCBD
● Live price
35.21%
Share price
$5.68
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$178.0K
Annual income
$27,022.57
Full PPCBD calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — PPCBD vs MRK

📍 PPCBD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPPCBDMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PPCBD + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PPCBD pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PPCBD
Annual income on $10K today (after 15% tax)
$2,992.96/yr
After 10yr DRIP, annual income (after tax)
$22,969.18/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, PPCBD beats the other by $14,640.77/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PPCBD + MRK for your $10,000?

PPCBD: 50%MRK: 50%
100% MRK50/50100% PPCBD
Portfolio after 10yr
$117.4K
Annual income
$18,410.35/yr
Blended yield
15.68%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

PPCBD
No analyst data
Altman Z
-18.6
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PPCBD buys
0
MRK buys
0
No recent congressional trades found for PPCBD or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPPCBDMRK
Forward yield35.21%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$178.0K$56.8K
Annual income after 10y$27,022.57$9,798.13
Total dividends collected$128.7K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PPCBD vs MRK ($10,000, DRIP)

YearPPCBD PortfolioPPCBD Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$14,221$3,521.13$11,206$366.19+$3.0KPPCBD
2$19,896$4,679.85$12,650$502.35+$7.2KPPCBD
3$27,408$6,119.13$14,407$694.19+$13.0KPPCBD
4$37,205$7,877.95$16,585$967.82+$20.6KPPCBD
5$49,803$9,994.16$19,342$1,363.89+$30.5KPPCBD
6$65,793$12,503.21$22,913$1,947.19+$42.9KPPCBD
7$85,835$15,436.81$27,662$2,823.89+$58.2KPPCBD
8$110,665$18,821.76$34,159$4,173.35+$76.5KPPCBD
9$141,091$22,678.96$43,337$6,308.80+$97.8KPPCBD
10$177,990$27,022.57$56,776$9,798.13+$121.2KPPCBD

PPCBD vs MRK: Complete Analysis 2026

PPCBDStock

Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.

Full PPCBD Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this PPCBD vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PPCBD vs SCHDPPCBD vs JEPIPPCBD vs OPPCBD vs KOPPCBD vs MAINPPCBD vs JNJPPCBD vs ABBVPPCBD vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.